Drugs like Ozempic could ‘significantly’ cut Alzheimer’s risk, study finds
Global News
New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.
GLP-1 drugs like Ozempic and Wegovy, commonly used for Type 2 diabetes and weight loss, may also offer significant protection against Alzheimer’s disease and dementia, according to new research.
Two major studies published Monday in JAMA Neurology found that GLP-1 medications are linked to a lower risk of cognitive decline in people with Type 2 diabetes.
One study found that GLP-1 drugs were associated with a 33 per cent reduction in the risk of dementia, while another class of diabetes medications, SGLT2 inhibitors, demonstrated an even greater benefit, cutting the risk by 43 per cent.
“We consider this the initial point, and the results are very promising, but there is other work that needs to be done,” explained Dr. Serena Guo, senior author of one of the studies and a pharmacoepidemiologist at the University of Florida College of Pharmacy.
SGLT2 inhibitors are a class of medications that help lower blood sugar by preventing the kidneys from reabsorbing glucose, allowing it to be excreted in urine. Common brand names include Farxiga, Jardiance and Invokana.
GLP-1 drugs, like Ozempic and Wegovy, are commonly used to manage Type 2 diabetes by helping control blood sugar levels. They work by boosting insulin, reducing sugar production in the liver and slowing down digestion.
Recently, GLP-1 medications have gained a lot of attention not only for their diabetes-fighting power but also for their ability to help with weight loss, making them popular even among those without diabetes.
Other studies have shown that GLP-1 drugs can also offer benefits for cardiovascular health, help protect against kidney disease, and now, potentially reduce the risk of dementia.
Run 3 Space | Play Space Running Game
Traffic Jam 3D | Online Racing Game
Duck Hunt | Play Old Classic Game
Health Canada has issued a recall for the Wooden Bunny Stacker toy by Ganz after it was found to contain unsafe levels of lead in one of its parts.
New research suggests babies and young children may be exposed to harmful chemicals from their mattresses — even ones sold in Canada.
The looming antitrust trial will be the first big test of President Donald Trump’s Federal Trade Commission’s ability to challenge Big Tech.
The easily preventable disease, declared eliminated in the U.S. in 2000, ripped through communities sprawling across more than 20 Texas counties.
As United States Health and Human Services Secretary Robert F. Kennedy Jr. urges Americans to get the measles vaccine, he's also casting doubt on it.
With polarizing political rhetoric reigning south of the border, Quebec and other provinces are hoping to attract American doctors to Canada.
Health Canada issued a recall for two popular products: the Fisher-Price Brunch and Go Stroller Toy and the Fisher-Price 3-in-1 SnugaPuppy Activity Center.
The United States will identify the cause of autism by September, Secretary of Health and Human Services Robert F. Kennedy Jr. said on Thursday.
Canada should seize the opportunity to turn the U.S. brain drain of doctors and scientists into its own brain gain, the Canadian Medical Association (CMA) said.
Calgary-based owner of Keystone pipeline, South Bow Corp., says North Dakota oil spill has been contained while cleanup continues.
While the infected in the hit HBO show are shown as becoming more monsters than humans, Dr. Jim Kronstad said that it is not the same in real life.
West Kelowna RCMP and Central Okanagan Search and Rescue said items belonging to a missing person were located near the slide, which came down on April 1.
As measles cases continue to rise in Canada, particularly in Ontario, one U.S. state is taking notice of the surge and warning its residents about travel.